Merck KGaA is hoping to position itself as a leader among companies looking to develop next-generation PARP inhibitors by teaming up with Italy's Nerviano Medical Sciences.
The German group has inked a collaboration agreement, which comes with a licensing option, with Nerviano for NMS-293, an early-stage oral selective PARP1 inhibitor
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?